Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
作者信息
Buryachkovskaya Liudmila, Lomakin Nikita, Melkumyants Arthur, Docenko Julia, Serebruany Victor
机构信息
National Medical Research Center of Cardiology, Moscow, Russia.
Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):e81-e82. doi: 10.1093/ehjcvp/pvab051.
Abstract
摘要
相似文献
1
Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?托珠单抗、血细胞与轻度新型冠状病毒肺炎：白细胞介素阻断导致血管保护延迟？
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):e81-e82. doi: 10.1093/ehjcvp/pvab051.
2
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.托珠单抗治疗 COVID-19 患者：新型疾病推荐药物。
Int Immunopharmacol. 2020 Dec;89(Pt A):107018. doi: 10.1016/j.intimp.2020.107018. Epub 2020 Sep 16.
3
Preemptive interleukin-6 blockade in patients with COVID-19.COVID-19 患者的预防性白细胞介素 6 阻断。
Sci Rep. 2020 Oct 8;10(1):16826. doi: 10.1038/s41598-020-74001-3.
4
Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.使用托珠单抗治疗后COVID-19肺炎的快速影像学改善。
Infection. 2021 Feb;49(1):195-196. doi: 10.1007/s15010-020-01449-w. Epub 2020 Jun 15.
5
Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.音频访谈：一种新型的严重急性呼吸综合征冠状病毒2疫苗以及对治疗方法的新审视
N Engl J Med. 2021 Mar 4;384(9):e46. doi: 10.1056/NEJMe2103680.
6
Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?用白细胞介素-6抑制剂治疗2019新型冠状病毒（COVID-19）：我们已经进展到那一步了吗？
Drug Discov Ther. 2020;14(2):100-102. doi: 10.5582/ddt.2020.03006.
7
Effects of Tocilizumab in COVID-19 patients: a cohort study.托珠单抗治疗 COVID-19 患者的效果：一项队列研究。
BMC Infect Dis. 2020 Dec 22;20(1):964. doi: 10.1186/s12879-020-05701-4.
8
Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.白细胞介素-6受体拮抗剂疗法治疗肾移植受者中由SARS-CoV-2驱动的炎症综合征。
Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.
9
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
10
Is IL-6 a key cytokine target for therapy in COVID-19?白细胞介素-6 是 COVID-19 治疗的关键细胞因子靶点吗？
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
引用本文的文献
1
Effect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19.舒洛地昔对轻度新型冠状病毒肺炎患者循环血细胞的影响
J Clin Med. 2022 Apr 2;11(7):1995. doi: 10.3390/jcm11071995.
本文引用的文献
1
Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?轻度 COVID-19 与血细胞-内皮细胞相互作用受损：是否考虑长期使用抗血栓药物？
Thromb Haemost. 2022 Jan;122(1):123-130. doi: 10.1055/a-1551-9911. Epub 2021 Sep 5.
2
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.COVID-19 住院患者使用托珠单抗的疗效：CORIMUNO-TOCI-1 随机临床试验的随访。
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.
3
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.COVID-19 中的免疫、内皮损伤和补体诱导的凝血异常。
Nat Rev Nephrol. 2021 Jan;17(1):46-64. doi: 10.1038/s41581-020-00357-4. Epub 2020 Oct 19.
4
Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 的疗效：系统评价和荟萃分析。
J Med Virol. 2021 Mar;93(3):1620-1630. doi: 10.1002/jmv.26509. Epub 2020 Sep 28.
5
Endothelial cells orchestrate COVID-19 coagulopathy.内皮细胞在新型冠状病毒肺炎凝血病中起关键作用。
Lancet Haematol. 2020 Aug;7(8):e553-e555. doi: 10.1016/S2352-3026(20)30215-5. Epub 2020 Jun 30.
6
Thromboinflammation and the hypercoagulability of COVID-19.新冠病毒感染的血栓炎症与高凝状态
J Thromb Haemost. 2020 Jul;18(7):1559-1561. doi: 10.1111/jth.14849. Epub 2020 May 26.
Zotero 插件